Financials
| Results for the year ended 31 December 2024 | May. 20, 2025 |
| Interim results for the six months to 30 June 2024 | Sep. 18, 2024 |
| Annual Report & AGM Notice | May. 09, 2024 |
| Results for the year ended 31 December 2023 | Apr. 30, 2024 |
| Interim results for the six months to 30 June 2023 | Sep. 13, 2023 |
| Results for the year ended 31 December 2022 | Mar. 30, 2023 |
| Interim Results | Sep. 06, 2022 |
Proxies
| Annual Report, AGM Notice & Circular | May. 27, 2025 |
| Result of AGM | Jun. 17, 2024 |
| Results of Annual General Meeting | May. 11, 2023 |
| Annual Report & AGM Notice | Apr. 12, 2023 |
| Result of AGM | Apr. 04, 2022 |
| Notice of AGM | Mar. 09, 2022 |
Ownership Update
| Notification of Major Holdings | Jul. 01, 2025 |
| Notification of Major Holdings | Jun. 26, 2025 |
| Director/PDMR Shareholding | Jun. 25, 2025 |
| Holding(s) in Company | Feb. 18, 2025 |
| Holding(s) in Company | Jan. 09, 2025 |
| Holding(s) in Company | Aug. 12, 2024 |
| Notification of Major Holdings | Jul. 10, 2024 |
Announcements
| Results of GM and AGM Meetings | Jun. 23, 2025 |
| FDA Orphan Drug Designation granted for POLB 001 | May. 27, 2025 |
| Result of upsized oversubscribed BookBuild Offer | May. 23, 2025 |
| Result of Placing and Notice of General Meeting | May. 20, 2025 |
| Proposed Fundraising to raise approximately £4.1M | May. 20, 2025 |
| Conference Participation in March & April 2025 | Mar. 27, 2025 |
| POLB 001 Patent Granted in Korea | Mar. 20, 2025 |